The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...

A surprise amount of Brits say they would take anti-obesity drugs if they were given to them for free on the ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

Credit: Jo Panuwat D/Shutterstock. On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the ...

Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, they have undesirable side effects. Now, scientists at the University of ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Wegovy is the world’s first weekly glucagon-like peptide-1 receptor agonist for long-term weight management. China’s National ...

About MBX 1416 MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a potential treatment for PBH. It was designed using the Company’s novel ...